DIQTA 1.0: Drug-Induced QT Prolongation Atlas

ALBUTEROL SULFATE

DIR Classification Postmarketing Surveillance Drug Property Information Reference

DIR Classification

Classification:Ambiguous

Severity Score:1.0

Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF

WARNINGS
Cardiovascular Effects
Albuterol Sulfate Syrup, like all other beta-adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of albuterol sulfate syrup at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown.

Postmarketing Surveillance

Contingency Table:

Current Drug

Other Drugs

QT Prolongation

24053

Other ADRs

121030

38260557

Odds Ratio = 0.513

Drug Property Information

ATC Code(s):

Active Ingredient:ALBUTEROL SULFATE

Active Ingredient UNII:021SEF3731

Drugbank ID:DB01001

PubChem Compound:2083

CTD ID:D000420

PharmGKB:PA448068

CAS Number:18559-94-9

Dosage Form(s):syrup

Route(s) Of Administrator:oral

Daily Dose:

Chemical Structure:

SMILE Code:
CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1

Reference

1: Repeat dosing of albuterol via metered-dose inhaler in infants with acute obstructive airway disease: a randomized controlled safety trial.

[Kaashmiri Mohammed,Shepard Julie,Goodman Brad,Lincourt William R,Trivedi Roopa,Ellsworth Anna,Davis Angela M]
Pediatr Emerg Care,2010 Mar;26(3):197-202. PMID: 20179658

Search for drugs: